<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062099</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO13-CH/ NIDeCo</org_study_id>
    <nct_id>NCT02062099</nct_id>
  </id_info>
  <brief_title>PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)</brief_title>
  <acronym>NIDeCo</acronym>
  <official_title>PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) is the most common cause of dementia in elderly subjects. AD is
      characterized by brain lesions like extracellular deposits of ß-amyloïd proteins in senile
      plaques and intracellular neurofibrillary tangles of hyper-phosphorylated tau protein, both
      of which are associated with the loss of neurons. The development of disease biomarkers for
      AD (Tau, PhTau and βamyloid dosing in the cerebrospinal fluid, brain MRI, amyloid PET imaging
      and fluorodeoxyglucose PET imaging) to identify the pathophysiological processes underlying
      cognitive impairment biomarkers, have been incorporated into revised diagnosis guidelines.

      Post-mortem human AD and AD animal model studies have reported inflammatory processes also
      implicated in the neuropathology of AD, and upregulated levels of pro-inflammatory cytokines.

      In vivo visualization of microglial activation has become possible with the development of
      molecular imaging ligands (tracers) for use with positron emission tomography (PET). The
      translocator protein (TSPO) formerly known as the peripheral benzodiazepine receptor (PBR), a
      receptor located in the outer membrane of mitochondria, is upregulated during
      neuroinflammation. So targeting TSPO with radiolabeled ligands for PET is considered as an
      attractive biomarker for neuroinflammation.

      The main aim of this pilot study is to quantify neuroinflammation, in terms of fixation and
      distribution of [18F] DPA-714(Binding Potential BP), and to study its relationship with
      amyloid load, measured with in [18F]AV-45 (Standard Uptake Values ratio) in cognitive
      decline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Molecular imaging of microglial activation could help us document the central inflammatory
      status of study subjects and assist us in designing future research studies particularly with
      respect to which subjects to enrol into clinical trials and to evaluate the benefit of
      specific therapies in selected groups, for example, by monitoring the effects of Aß
      immunization.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fixation and distribution of [18F]DPA-714 (Binding Potential BP)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>[18F]AV-45 Standard Uptake Values ratio</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between [18F]DPA-714 uptake and cognitive, affective symptoms at baseline.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Memory Complaint</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Memory complaint /MCI/ mild to moderate MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Memory complaint (without cognitive decline): 12 patients/ Mild Cognitive Impairment: 12 patients/ Mild to moderate Alzheimer Disease: 12 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment</intervention_name>
    <arm_group_label>Memory complaint /MCI/ mild to moderate MA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Criteria common to all participants:

          -  Signed informed consent

          -  Age ≥ 60 years old (60-80 years old)

          -  Native language: French

          -  Correct sensory abilities (hearing aids accepted) to perform the tests

          -  Affiliated to a social security system

        Criteria for patients with mild to moderate Alzheimer disease defined according to the
        NINCDS-ADRDA {McKhann, 2011 # 408}:

          -  MMS between 20 and 25

        Criteria for amnestic MCI patients:

          -  Amnestic mildcognitive disorder evoking a MA in pre stage dementia {Dubois, 2010 #
             273, Dubois, 2007 # 42; Pertersen, 1999 # 21, Albert, 2011 # 409} older than 60 years.

        Criteria for patients with isolated memory Complaint (Without Cognitive Decline):

          -  MMS score ≥ 26

          -  Normal performance by age and educational level
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline HOMMET, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Tours (CMRR)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline HOMMET, PhD</last_name>
    <phone>+33247479780</phone>
    <email>caroline.hommet@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie GISSOT, MD</last_name>
    <phone>+33234379653</phone>
    <email>valerie.gissot@univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline HOMMET, PhD</last_name>
      <phone>+33247479780</phone>
      <email>caroline.hommet@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie BEAUFILS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karl MONDON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria-Joao SANTIAGO-RIBEIRO, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe COTTIER, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Arlicot N, Vercouillie J, Ribeiro MJ, Tauber C, Venel Y, Baulieu JL, Maia S, Corcia P, Stabin MG, Reynolds A, Kassiou M, Guilloteau D. Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nucl Med Biol. 2012 May;39(4):570-8. doi: 10.1016/j.nucmedbio.2011.10.012. Epub 2011 Dec 14.</citation>
    <PMID>22172392</PMID>
  </results_reference>
  <results_reference>
    <citation>Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, La Joie R, Tafani M, Hommet C, Chételat G, Mondon K, de La Sayette V, Cottier JP, Beaufils E, Ribeiro MJ, Gissot V, Vierron E, Vercouillie J, Vellas B, Eustache F, Guilloteau D. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):621-31. doi: 10.1007/s00259-011-2021-8. Epub 2012 Jan 18.</citation>
    <PMID>22252372</PMID>
  </results_reference>
  <results_reference>
    <citation>La Joie R, Perrotin A, Barré L, Hommet C, Mézenge F, Ibazizene M, Camus V, Abbas A, Landeau B, Guilloteau D, de La Sayette V, Eustache F, Desgranges B, Chételat G. Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. J Neurosci. 2012 Nov 14;32(46):16265-73. doi: 10.1523/JNEUROSCI.2170-12.2012.</citation>
    <PMID>23152610</PMID>
  </results_reference>
  <results_reference>
    <citation>Beaufils E, Dufour-Rainfray D, Hommet C, Brault F, Cottier JP, Ribeiro MJ, Mondon K, Guilloteau D. Confirmation of the amyloidogenic process in posterior cortical atrophy: value of the Aβ42/Aβ40 ratio. J Alzheimers Dis. 2013;33(3):775-80. doi: 10.3233/JAD-2012-121267.</citation>
    <PMID>22986776</PMID>
  </results_reference>
  <results_reference>
    <citation>Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, Nicolas G, Venel Y, Hommet C, Baulieu JL, Cottier JP, Roussel C, Kassiou M, Guilloteau D, Ribeiro MJ. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7(12):e52941. doi: 10.1371/journal.pone.0052941. Epub 2012 Dec 31.</citation>
    <PMID>23300829</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <last_update_submitted>February 11, 2014</last_update_submitted>
  <last_update_submitted_qc>February 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

